http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2390370-A2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4fcdab57930cafaf53088e9cc804fdec |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
filingDate | 2008-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_679c7cb78c11af7609e7bb23ca3ec07a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3abfdb379eabd0f6def76296088c18b7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_089aa844e8a29fb9fb56eb16da5da5c3 |
publicationDate | 2011-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-2390370-A2 |
titleOfInvention | A method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent |
abstract | The present invention relates to a method for predicting a response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent, said method comprising the steps of: a) obtaining a biological sample from said patient; b) determining the pattern of expression level of at least one gene of the group comprising AKR1C1, MLPH, ESR1, PGR, COMP, DCN, IGKC, CCL5, FBN1 and/or UBE2C, or of genes coregulated therewith, in said sample; c) comparing the pattern of expression levels determined in (b) with one or several reference pattern(s) of expression levels; d) identifying at least one marker gene; e) determining a molecular subtype for said sample on the basis of (d); and f) predicting from said molecular subtype response of a tumor for a chemotherapeutic agent, wherein the molecular subtype is selected from the group comprising the subtypes basal, stromal-high, stromal-low, luminal A, immune system-high, immune system-low, proliferation-high and/or proliferation-low. |
priorityDate | 2007-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 650.